About Totient
Totient is a Healthcare company based in Cambridge (United States) founded in 2017 by James Sietstra and Deniz Kural, and was acquired by AbSci in June 2021. Developer of a drug discovery platform for cancer and autoimmune disease by using artificial intelligence. Totient has raised $10.5 million across 3 funding rounds from investors including AbSci, Viva Biotech and Viva BioInnovator. The company has 26 employees. Its chief executive, as recorded, is Deniz Kural. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is SBGD, INC. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
Developer of a drug discovery platform for cancer and autoimmune disease using artificial intelligence. The company uses immunoinformatics-algorithms, machine learning techniques, and tertiary lymphoid structures (TLS) for the identification of novel tissue-specific antigens and antibodies expressed by the cancer-affected tissues. The company develops cancer therapeutics by reconstructing antibodies from tissues affected by autoimmunity, infections, and cancer. The company has developed antibodies against novel extracellular oncology targets that include GAGE1, GAGE2A, LIVIN (BIRC7), PCNA, ANXA1, C4BPB, HCLS1, GPR83, and IL14A.
- Headquarters Cambridge, United States
- Employees 26
- Founders James Sietstra, Deniz Kural
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website totient.bio
- Social LinkedIn X
- Acquired by AbSci (Jun 2021)
- Legal Name Sbgd, Inc.
Funding Insights of Totient
Totient has successfully raised a total of $10.5M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10.5M
- Total Rounds 3
- First Round $500,000
(Mar 2019)
- Investors Count 8
All 3 funding rounds of Totient with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | Seed | – | CerraCap Ventures | – | |
| Sep 2020 | $10M | Seed | – | Tau Ventures, Kaitai Capital Management | |
| Mar 2019 | $500,000 | Seed | – | Viva BioInnovator | – |
9 investors in total: 8 institutional and 1 angel.
Investors in Totient
Totient has secured backing from 9 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include AbSci, Viva Biotech and Viva BioInnovator.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage tech companies in Asia and the US are funded. | cerracap.com | Costa Mesa, United States | ||
Seed-stage startups are funded by this venture capital firm. | tauventures.com | Palo Alto, United States | ||
Kaitai Capital is engaged in innovation investment management services. | kaitaicapital.com | Hangzhou, China | ||
Investments in life science startups are made by Mission BioCapital. | missionbiocapital.com | San Francisco, United States | ||
Biotechnology startups are incubated and funded by Viva BioInnovator. | 2014 | vivabioinnovator.com | Shanghai, China | |
Drug discovery and development research services are provided. | 2006 | vivabiotech.com | Shanghai, China | |
Active, long-term growth equity investments are provided globally. | sandscapital.com | Arlington, United States | ||
JM Jonathan Milner | British angel investor, founder of Abcam, active in biotech and life sciences. | unknown_b4661a4484ce4b86a | ||
AI-based technology is used for recombinant protein production in therapeutics. | 2011 | absci.com | Vancouver, United States |
Investor details for Totient
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Totient
30 people are tracked at Totient (16 in leadership, 5 in board & advisors, 9 in team); the tracked headcount is 26.
| Name | Role | Group |
|---|---|---|
James Sietstra | Co-Founder | Leadership |
Deniz Kural | Co-Founder & CEO | Leadership |
Sean McClain | Founder & CEO | Leadership |
Karin Wierinck | Chief People Officer | Leadership |
Andreas Busch | Chief Innovation Officer | Leadership |
Nikhil Goel | Chief Strategy Officer | Leadership |
Jared Sharp | Associate Director | Leadership |
Michael Mangone | Vice President Of Business Development | Leadership |
Beverly Crider | Director, Alliance Management | Leadership |
Yukte Sharma- Dayal | Sr. Executive Assitant To CEO And CFO | Leadership |
Mario Sanches | Director Of Business Development | Leadership |
Wen Sha | Vp, Chief Of Staff | Leadership |
Chris Ulm | VP, Business Development & Alliance Management | Leadership |
Ben Golomb | Associate Director, Alliance Management & Growth Strategy | Leadership |
Tom Cordaro | Vice President Of Business Development | Leadership |
Chad Taylor | Head Of IT | Leadership |
Zachariah Jonasson | Chairman | Board & advisors |
V. Bryan Lawlis | Director | Board & advisors |
Gustavo Mahler | Director | Board & advisors |
Andy Pihl | Director | Board & advisors |
10 more people are available in the full profile.
Complete people profiles for Totient
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Totient
4 dated milestones of Totient across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Totient is founded.
- Funding First funding round of $500K.
- Funding Latest funding round, Seed,.
- Exit Acquired by AbSci.
Competitors of Totient
Totient has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of Totient
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Totient (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Totient
Complete news archive for Totient
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Totient
Totient was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Totient is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Deniz Kural is the CEO of Totient, as recorded in our data. They have also founded this company.
Totient is a funded company, having raised a total of $10.5M across 3 funding rounds to date. The company's 1st funding round was a Seed of $500K, raised on Mar 2019.
Totient has 26 employees.
Developer of a drug discovery platform for cancer and autoimmune disease using artificial intelligence. The company uses immunoinformatics-algorithms, machine learning techniques, and tertiary lymphoid structures (TLS) for the identification of novel tissue-specific antigens and antibodies expressed by the cancer-affected tissues. The company develops cancer therapeutics by reconstructing antibodies from tissues affected by autoimmunity, infections, and cancer. The company has developed antibodies against novel extracellular oncology targets that include GAGE1, GAGE2A, LIVIN (BIRC7), PCNA, ANXA1, C4BPB, HCLS1, GPR83, and IL14A.
Totient's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
Totient has 9 investors. Key investors include AbSci, Viva Biotech, Viva BioInnovator, CerraCap Ventures, and Tau Ventures.
Totient operates through Sbgd, Inc..
Yes. Totient was acquired by AbSci in June 2021.